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Abstract
Background: To understand cancer-related modifications to transcriptional programs requires
detailed knowledge about the activation of signal-transduction pathways and gene expression
programs. To investigate the mechanisms of target gene regulation by human estrogen receptor α
(hERα), we combine extensive location and expression datasets with genomic sequence analysis.
In particular, we study the influence of patterns of DNA occupancy by hERα on expression
phenotypes.
Results: We find that strong ChIP-chip sites co-localize with strong hERα consensus sites and
detect nucleotide bias near hERα sites. The localization of ChIP-chip sites relative to annotated
genes shows that weak sites are enriched near transcription start sites, while stronger sites show
no positional bias. Assessing the relationship between binding configurations and expression
phenotypes, we find binding sites downstream of the transcription start site (TSS) to be equally
good or better predictors of hERα-mediated expression as upstream sites. The study of FOX and
SP1 cofactor sites near hERα ChIP sites shows that induced genes frequently have FOX or SP1
sites. Finally we integrate these multiple datasets to define a high confidence set of primary hERα
target genes.
Conclusion: Our results support the model of long-range interactions of hERα with the
promoter-bound cofactor SP1 residing at the promoter of hERα target genes. FOX motifs co-
occur with hERα motifs along responsive genes. Importantly we show that the spatial arrangement
of sites near the start sites and within the full transcript is important in determining response to
estrogen signaling.
Background
Human estrogen receptor alpha (hERα) is an essential
nuclear receptor regulating female development and
reproductive functions. In the context of breast cancer,
both hERα protein concentration and mRNA abundance
have been shown to be associated with specific cancer
sub-types and to influence survival rates [1-3]
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responsive elements (EREs) and to activate transcription
of its target genes, in particular early estrogen-responsive
genes [4-7]. It was also shown that some hERα targets,
such as c-Myc, lack the ERE, but instead contain AP1 or
SP1 binding sites, which appear to be essential for tran-
scription in vitro [5,8,9]. Studies about how the estrogen
receptor eventually induces transcription of its target
genes have lead to the identification of complex interac-
tions between hERα and a large number of cofactors
[7,10,11].
Several recent approaches have been developed to identify
hERα targets in vivo on a genome-wide scale. Correlation
studies have used mRNA expression levels [12] from com-
pendia of cancer samples to identify estrogen induced
genes in cells. Other approaches have resulted in refined
binding motifs from sequence analysis [13], novel candi-
date regulatory elements from comparative genomics, and
most recently high-resolution maps of binding sites from
ChIP-chip [14-16].
From ChIP-chip studies, Carroll and colleagues [15] drew
the conclusion that estrogen receptor can activate tran-
scription when bound to distal enhancers and that it is
assisted in this function by the transcription factor
FOXA1. The authors eventually refined their conclusions
stating that FOXA1 can translate epigenetic signatures into
cell-type specific transcriptional programs; i.e. FOXA1
recruits hERα, or androgen receptor, which, in turn, may
act as stabilizer for FOXA1 binding [17]. Enrichment of
FOXA1 binding seems to be most evident around inter-
genic ERE's, and almost undetectable at promoters [16].
Another approach uses a ChIP paired end diTags (ChIP-
pet) technique to map hERα binding sites [18]. The
authors found that the majority of hERα binding events
happen in intragenic regions, in particular in introns;
hERα sites at promoters are capable of inducing transcrip-
tion, as are hERα binding sites in distal enhancers, as pre-
viously reported [15]. The ChIP-pet investigation [18]
found poor conservation of estrogen receptor binding
sites between human and mouse, and overlaps in the con-
sensus motifs of hERα and putative transcription factor
partners such as AP1.
A previous study [19] isolated 12 transcriptionally active
genomic sites which recruit hERα. It showed one case of
an ERE located 3.7 kb downstream of the first transcrip-
tional start site of a target gene. Moreover, the presence of
the SP1 transcription factor at the promoter of genes
induced by hERα was shown by ChIP. Nevertheless, SP1
binding was not influenced by estradiol, pointing to inde-
pendent mechanisms of recruitment. Further expression
profiling analyses [20] tackled the same question employ-
ing an inhibitor of transcription, cycloheximide, to dis-
criminate between primary and secondary targets. The
authors concluded that AP1 and GC-box binding factors
such as SP1, are enriched around the transcription start
sites of up-regulated primary targets. Thus local nucle-
otide composition seems to play a role in defining active
ERE's. This observation is supported by in silico investiga-
tions [13] reporting that extending the hERα PWM with
CG rich flanks improves the prediction of functional
hERα binding sites. Transcriptional regulation of hERα
secondary target genes is, on the other hand, controlled by
E2F, a transcription factor involved in cell-cycle regulation
[20].
In this study we investigate mechanisms of target gene reg-
ulation by hERα by studying the relationship between
EREs and gene expression. For this, we combine inde-
pendent genome-wide ChIP analyses with large-scale
microarray studies of estrogen response as well as
genomic sequence analysis. In this context, we also inves-
tigate the roles of binding sites of known cofactors such as
FOX and SP1 in silico. Our analysis confirms important
characteristics of EREs such as their intergenic localiza-
tion, the presence of cofactor sites, and GC biased local
nucleotide composition. Unexpected however, was the
finding that stronger and weaker hERα sites show differ-
ent localization patterns with respect to annotated tran-
scripts. Specifically, weak sites are enriched near
transcription start sites, while stronger sites show no posi-
tional bias. We then study the relationship between bind-
ing and expression patterns and find binding sites
downstream of the transcription start site to be equally
good or better predictors of hERα-mediated expression
than upstream sites. Studying FOX and SP1 cofactor sites
near hERα ChIP sites shows that both factors reinforce the
response to estrogen. Taken together, our results argue
against significant hERα activity as a promoter bound
transcription factor, and rather favor the long-range inter-
action model involving SP1 as the main mechanism of
hERα-mediated response to estrogen. Finally we compile
a reliable set of direct targets related to both normal and
pathological states using our integrative approach.
Results
Strong ChIP-chip sites co-localize with strong hERα 
consensus sites
We analyzed ChIP data for hERα measured by Affymetrix
tiling array [15] using our signal estimation method SLM
[21]. This method provides a quantitative measure (t-
score) of the ChIP enrichment that allows strong and
weak signals to be differentiated. As a first assessment of
the fidelity of the binding regions, we measure the pres-
ence of canonical EREs (15 bp consensus motifs; cf. Meth-
ods) within 500 bp of mapped ChIP sites. For this, we
designed a Hidden Markov Model (HMM) model forPage 2 of 13
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per sequence (cf. Methods). Specifically, we compute pos-
terior probability to find EREs at each position along the
1 kbp sequences centered on the sites identified by SLM.
We observe that the expected occurrences of EREs show a
monotone sigmoidal dependency on the corresponding t-
scores (Fig. 1A). This behavior allows to define cutoffs for
selecting high confidence ChIP sites in a natural manner:
for t~16 each site has on average one ERE, which is double
the number found for t~10. The actual cutoffs were deter-
mined from a sigmoidal fit to the median occurrence in
function of t-scores (Fig. 1A). We thus define a set 2359
high stringency sites with t = 16 and a set of 7444 lower
stringency with 10<t<16. The latter group could reflect
weaker binding sites stabilized by the presence of co-fac-
tors, or give indications of cross-linking of long-range
interactions between hERα and other factors [14]. Inter-
estingly, we find that the genomic coordinates of EREs
(posterior probability > 0.5) fall within a narrow window
of the estimated positions of ChIP sites. Namely, 80% of
EREs resides within 200 bp from the position of maximal
ChIP enrichment as modeled in the SLM method (Fig. 1B
and [see Additional file 1]). This means that although the
resolution of ChIP is limited by the size of the fragments,
typically about 1 kb, the position of the binding site
occurs in 80% of cases within 200 bp of the maximum
enrichment.
Nucleotide bias near hERα sites
Studying the nucleotide composition around hERα bind-
ing sites requires a precise mapping of the hERα motif on
the genomic sequence, so that sites can be aligned with
respect to EREs. We inspect all high and lower stringency
sites with at least one ERE occurrence (posterior probabil-
ity > 0.5) within 1 kbp of the reported ChIP-chip site. We
find that the sequence at these sites is GC-rich (~46% GC)
compared to the genomic background composition
(~40%) and varies with t-score, the maximum GC-con-
tent being found for sites with t~10 (~50% GC, [see Addi-
tional file 2], panelB). Moreover, the average sequence
composition exhibits an increase in GC-content of ~4% in
200 bp region immediately around the hERα binding site
(Fig. 2A). We note that this is not due to the bias in the
ERE itself (GC is 60%) but due to the flanking bases. In
addition, within the studied window, the GC bias stays
higher for the weaker sites, consistent with the higher fre-
quency of weak sites near transcription start sites (cf. next
paragraph).
Localization of ChIP-chip sites relative to genome 
annotations
To further characterize hERα sites, we examine their local-
ization relative to known genes. We use UCSC annota-
tions (cf. Methods) and find that high stringency hERα
binding sites (t>16) occur both in intergenic regions
(~56%) and along genes (~44%) (Table 1). Interestingly,
we observe an enrichment of low stringency sites
(10<t<16) binding sites within 500 bp of transcription
start sites (TSSs) which was not reported previously. In
particular 12% of sites within 50 bkp of a TSS are closer
than 500 bp to the TSS (Fig. 2B, left panel). In compari-
son, no detectable enrichment is present near the poly-
adenylation site (PAS) (Fig. 2B, left panel). Finally, a
remarkable fraction of sites, 16.7%, lies in repeats (cf.
Table 1). This fraction is higher than the 5.3% reported by
previous analysis of the ChIP-chip data [15], but not as
high as the 27.9% reported by ChIP-pet [18].
The number of binding sites downstream of the TSS is a 
good indicator of hERα-mediated induction
To investigate how the occupation of hERα binding sites
leads to gene induction, we assess the influence of hERα
binding on expression phenotypes. The assessment
requires appropriate assignment of a binding site to the
target gene: generally a binding site is considered to influ-
ence the expression of a gene if it lies within a predefined
window around the TSS or the gene. Previous studies
[7,14-19] have used different windows: tight cis-regula-
tory regions upstream of TSS [16]; 50 kbp windows
around the promoters of responsive genes [15]; 100 kbp
around the promoters of cancer related genes [18]. Here
we assess which definition is best at discriminating
induced genes. For this, we quantify the expression
response to estrogen for each transcript using four inde-
pendent datasets probing different aspects of estrogen sig-
naling (cf. Methods). We will focus mainly on two
datasets: an expression compendium of cancer tissue sam-
ples [12] and a study on MCF7 cells where secondary tar-
get activation has been blocked by addition of
cycloheximide, an inhibitor of protein synthesis [20]. For
breast cancer samples, we expect that primary targets of
ESR1 will correlate with ESR1 mRNA abundance as pro-
tein concentration and mRNA abundance have been
shown to associate with cancer sub-types [12] (cf. linear
model, methods). Taken together, the different experi-
mental settings give us a broad picture of the activity of
hERα and its targets. We compare the various assignments
of sites using receiver operating characteristic (ROC) anal-
ysis, a commonly used methodology to assess the tradeoff
between the sensitivity and specificity of predictors.
We first compare the performance of proximal and
upstream sites vs. proximal and downstream binding
sites. We find that the number of binding sites covering
the 20 kbp downstream of the TSS tend to be a better dis-
criminator than the number in the equivalent upstream
region. Though the ROC curves show little differences, the
trend suggests that downstream sites yield higher sensitiv-
ity at almost identical specificity for each operative point
(Fig. 3). Different sets of binding sites, i.e. high, low strin-Page 3 of 13
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EREs and ChIP sitesFigure 1
EREs and ChIP sites. A. Number of hERα sites for 1 kbp sequences centered around the ChIP sites identified by SLM. The 
number of sites is computed from a Hidden Markov Model (cf. Methods) using posterior decoding. Results are stratified in 
function of the strength of the binding site (t-score). The density profile (red) shows bimodality for high t-scores. The median 
(dots) is calculated in bins of one unit in t-scores. A smoothed estimator (in grey) has been added as visual aid. The cut-offs 
used for defining highest (t < 16) and lower stringency sites (t > 10) are indicated with vertical lines. The monotonous trend 
can be approximated by a sigmoid (tanh) function with half-height at t~10 and saturating at t~16 (>90%). B. Left: Average occu-
pation profile at each genomic position computed using posterior decoding for the hERα consensus (e.g. 0.01 means that 1% of 
sequences have an ERE at this precise position). The profile is centered on the mode of the ChIP-chip site (red dashed line). 
Right: Fraction of EREs within a given radius of the mode of the ChIP signal. The ChIP sites identified with SLM have a width of 
about 1 kbp (width of the peak) while the binding sites for the 80% sites with a consensus (one position with posterior proba-
bility >0.5) are found within 200-bp of the mode in the t-profile.
BMC Genomics 2009, 10:381 http://www.biomedcentral.com/1471-2164/10/381gency ChIP sites, or ChIP-pet sites [18], show slightly
altered sensitivity and specificity, but the downstream
sites perform consistently better than upstream sites (Fig.
3 and [see Additional file 3]). We remark that few genes
have more than one site within 20 kbp of the TSS, thus
resulting in low sensitivity at high specificity; however, the
set of genes with more than one site is highly enriched for
direct targets, the enrichment being the slope of the line
connecting the operative point to the origin.
Secondly, we compare definitions with varying regulatory
region sizes. We use the number of binding sites in the
region as a discriminator for estrogen sensitive genes (Fig.
4, [see Additional file 4] and [see Additional file 5]) and
introduce the number of binding sites along the transcript
as a new metric for hERα-mediated gene induction. This
definition refers to sites along the whole length of the
transcript from 5 kbp upstream of the transcription start
site to 5 kbp downstream of the poly-adenylation site. We
observe that the operative points for the different defini-
tions lie on the same envelope, bounded on the left side
by the ROC curve for the number of binding sites along
the transcript (Fig. 4, [see Additional file 4] and [see Addi-
tional file 5]). At equal sensitivity, the number of sites
Characteristics of weak and strong ChIP sitesFigure 2
Characteristics of weak and strong ChIP sites. A. Average nucleotide composition profile for ChIP sites with ERE con-
sensus sites (posterior probability > 0.5). The sequences are centered on the ERE. Both sets, the low (left panel) and high (right 
panel) stringency sites, show a maximum GC enrichment within 200 bp of the ERE. Notice that GC content has not reached 
genome wide baseline at +/- 2.5 kbp, and drop-off is faster for the stronger sites (right). Each gray dot represents the mean fre-
quency at one position, smoothed mean (black) +/- 2SD (gray) and shown as lines. B. Localization of hERα binding sites relative 
to annotated transcription start sites (TSSs) and poly-adenylation sites (PASs). The percentage of occurrence is calculated rel-
ative to the number of sites in the full window (± 50 kbp of TSS or of PAS, bin size 500 bp). Coordinates are taken positive in 
the transcript direction but results show absence of directionality in the profiles. Left panel: Distribution of distances from 
TSSs for sites with 10<t<16 mapped in the 5' regions. The noticeable peak around the TSS covers 12% of the total number of 
sites in the region. We thus find a tight colocalization with the TSS (defined as 0, green profile) for a subset of sites. In contrast, 
no colocalization is evident for the PAS (red profile). Right panel: Distribution of distances from TSSs for sites with t>16 
mapped in the 5' regions. In this case, sites are uniformly distributed in the 50 kbp around the TSS (green profile) and around 
the PAS (red profile).Page 5 of 13
(page number not for citation purposes)
BMC Genomics 2009, 10:381 http://www.biomedcentral.com/1471-2164/10/381along the transcript achieves comparable or better specifi-
city (Fig. 4, black curve) than the other definitions in both
expression datasets. Taken together, these results show
that ERα sites located downstream of start sites are equally
or more effective at inducing genes than upstream sites.
In a complementary analysis, we study the ranks of induc-
tion in function of the number of hERα sites along tran-
scripts. Here the ranks are taken as the merged ranks from
the cancer expression compendium and primary target
datasets. We find that the ranks clearly correlate positively
with the number of sites both for the ChIP-chip and ChIP-
pet sites. The latter shows a more pronounced effect indi-
cating that ChIP-pet sites occur with preference near
strongly induced targets (Fig. 5A). The positive correlation
is generally unchanged when we restrict the sites to those
harboring a good instance of an ERE, but note that it is
increased in case of two ChIP-pet sites (Fig. 5B). Thus sites
with EREs are only marginally more prone to lead to
increased transcriptional response.
Signatures of FOX and SP1 cofactor sites near hERα ChIP 
sites
Though the ERE is the dominant recognition sequence for
strong ChIP sites (t>16), other transcription factors are
also involved in the regulation of target genes by direct
interaction with hERα at its specific sites [14,17,19]. We
test the contribution to gene induction by analyzing the
presence or absence of co-factor sites. We map the cofac-
tors sites based on their consensus sites by extending the
cyclic HMM model to reported co-factors of hERα:
FOXA1, AP1 and SP1 (cf. Methods, [see Additional file
1]). We also include E2F as this factor is known to regulate
secondary targets of the hERα signaling cascade [20]. We
find the SP1 consensus to be most represented in low
stringency ChIP sites (10<t<16), and observe a concurrent
Table 1: Number of hERα sites relative to genome annotations 
and repeats.
t-score > 16 Total In genes Intergenic In repeats
Number of sites 2359 1041 1318 396
Columns 1–3: Detected sites and their positions with respect to 
annotated transcripts
(UCSC genome browser, hg18).
Column 4: Detected sites residing in regions marked as repeats by 
RepeatMasker as reported in UCSC genome browser tables.
To be associated with a transcript, a site is required to lie between -5 
kb and +5 kb of the annotated boundaries (transcription start site and 
poly-adenylation site). A complete list is available upon request to the 
authors. The smoothing used in SLM is σ = 200 bp [21].
ROC analysis for comparing the ability of upstream or down-stream ChIP sites t  predict induced genesFigure 3
ROC analysis for comparing the ability of upstream 
or downstream ChIP sites to predict induced genes. 
In each experiment, the induced genes (positives) are taken 
as the 1% highest ranking transcripts. The remaining 99% are 
taken as the negatives. Note that for discrete data such as 
the number of sites in a specific genomic window, ROC anal-
ysis consists in a set of operative points (cf. Methods). The 
number of sites downstream of the TSS (light curves) shows 
the best performance among all the definitions tested (high 
stringency and low stringency ChIP-chip, ChIP-pet). Shown 
are the cancer expression compendium [12] and the study 
on primary estrogen receptor targets [20]. Further expres-
sion sets are shown in [see Additional file 3].
ROC analysis to compare the ability of ChIP sites in variably sized windows to predict induced genesFigure 4
ROC analysis to compare the ability of ChIP sites in 
variably sized windows to predict induced genes. Posi-
tives and negatives are taken as in Fig. 3. Number and defini-
tion of operative points is as in Fig. 3. The discrete curves lie 
on the same envelope, but the number of sites along the 
transcript (black curve) shows the best performance for all 
the sites definitions used (high stringency and low stringency 
ChIP-chip, ChIP-pet). The expression datasets are the cancer 
expression compendium and the study on primary estrogen 
receptor targets. In each experiment, the induced genes 
(positives) are taken as the 1% highest ranking transcripts. 
The remaining 99% are taken as the negatives. The same 
analyses using different definitions of sites (high stringency or 
ChIP-pet) are given in [see Additional file 4]. Further expres-
sion sets are analyzed in [see Additional file 5].Page 6 of 13
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sequences (t>16), these two signals reach similar occur-
rences (a median of 0.7 sites) and appear to follow a sim-
ilar slowly increasing trend as the EREs ([see Additional
file 1], red and green profiles). At the stringencies imple-
mented in our HMM, AP1 occurrences are uniform over
the full range of t-scores while E2F motifs are rare ([see
Additional file 1], orange profile), consistent with the role
of E2F in the induction of secondary targets [20]. We find
similar spatial profiles for the cofactor sites as in [15], i.e.
a bias towards the position of the maximal ChIP-chip sig-
nal for the EREs (Fig. 1B), for FOXA1 sites and for AP1
sites (not shown). In further characterizing the FOXA1
sites, we find no difference between the log-likelihood of
the FOXA1 in the high-stringency sites and the log-likeli-
hood of other motifs from the FOX factors [see Additional
file 6]. The observed signal is thus to be attributed to a
generic FOX site rather than specifically to FOXA1.
Induced genes have ChIP sites with FOX or SP1 sites
In order to study the dependency of hERα mediated
induction on co-factors, we stratify the ChIP sites along
the transcript according to the presence of FOX and SP1.
FOX has been reported to be involved in the regulation of
Response to hERα increases in function of the number of ChIP sites along transcriptsFigure 5
Response to hERα increases in function of the number of ChIP sites along transcripts. Ranks of the induction 
scores are shown as boxplots in function of the number of ChIP sites. In B-D, ChIP sites are further filtered according to the 
presence or absence of consensus elements for hERα (A) or FOX (C, D). A motif is assigned to a binding site if the occupancy, 
computed using posterior decoding, is greater than 0.5 (cf. Methods). The ranks of the induction scores of the cancer expres-
sion compendium and of the study on primary estrogen receptor targets have been pooled to avoid small sample size effects. 
Significance of the comparisons is assessed using the Wilcoxon rank sum test, i.e. comparison between equally colored distri-
butions are made. A-B. Effect of ERE motifs. For ChIP-pet sites the presence of an ERE improves the correlation between 
ranks and number of sites (orange boxes). No statistically significant improvement is detected for the ChIP-chip sites (blue 
boxes). C-D. Effect of FOX motifs. In addition to the presence of an ERE, the presence of a FOX motif improves significantly 
the association for the ChIP-pet sites (red box). Comparison with panel B (black boxes) indicates that many ChIP-pet sites with 
EREs also have FOX sites. Despite a shift in the distribution to higher ranks, no statistically significant improvement is detected 
for the ChIP-chip sites (purple boxes) with a FOX site.Page 7 of 13
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chromatin prior to hERα recruitment [14,15,17]. On the
other hand, SP1 is a GC-box bound enhancer associated
with the activity of the transcription machinery [22,23]
and frequently localized in the proximity of TSSs [21,24].
As expected, we find a strong enrichment of SP1 sites for
sites near promoters, compared to GC-rich binding sites
located in non-promoter proximal regions ([see Addi-
tional file 2], panels C-D). The analysis of hERα sites with
EREs, stratified according to FOX sites, shows that the cor-
relation with induction is preserved independently of
FOX sites. However, the presence of FOX sites shifts the
distribution toward higher induction in the case of the
ChIP-pet sites (p-val < 0.01, rank test, Figs. 5C–D, red
square). Separately we also consider hERα ChIP sites
around the TSSs harboring GC-boxes (SP1 sites). Clearly,
the set of targets with one binding site harboring a GC-box
is strikingly enriched for induced genes, both in the case
of ChIP-chip mapping and in the case of ChIP-pet map-
ping (Fig. 6 and fifth column of [see Additional file 7]).
Together, the analysis of putative cofactor sites is consist-
ent with an activating role for the FOX factor next to EREs,
while the role of SP1 sites in mediating response to estro-
gen at promoter proximal ChIP sites is very clear, irrespec-
tive of EREs.
High confidence hERα target genes
As reported targets tend to differ across experiments [7],
we used these multiple datasets to identify 35 genes with
at least two high-stringency ChIP-chip sites, one ChIP-pet
site along their full-length transcript and ranking in the
top 10% of hERα responding genes (Table 2). 12 of these
genes have previously been reported as direct targets of
hERα [14,15,18,19] and they have been associated with
the transduction of estrogen signaling activity. All of these
12 direct targets show the presence of at least one ERE
along their transcript, often accompanied by one or more
FOX motifs. Three known targets also exhibit SP1 motifs
in their promoter regions (Table 2, 4th column).
Of the remaining 23 genes, 3 genes (arsg, erbb4 and vav3)
are part of the estrogen signaling pathway, and two are
involved in the development of the upper body: with the
only exception of arsg, these genes exhibit a high number
of EREs and of FOX sites (Table 2, 2nd and 3rd columns).
Eight genes are associated with cancer [18,19], or
appeared upregulated in previous cancer studies [25-27].
Two of them (cyp24a1 and stard10) are specifically associ-
ated with breast cancer [25-27]. We observe that these
genes tend to have both EREs and FOX sites, but no clear
SP1 site at promoters. In addition, the number of EREs
seems to be higher than the number of FOX sites. Except
for c6orf97, a 127 kbp long open reading frame located
upstream of the esr1 gene, the remaining ten hERα targets
have not yet been associated to estrogen signaling or can-
cer activity. Though it is unclear how these targets may be
implicated in estrogen signaling, we find that anxa9, arl3
and atrnl1 are recruited during vesicle trafficking and sig-
naling, probably performing relevant functions down-
stream of the estrogen response. Further experiments will
be needed to clarify their role downstream of hERα.
Discussion
Properties of hERα binding sites measured in ChIP 
experiments
We analyzed raw genome-wide ChIP-chip data [15] using
our previously developed SLM algorithm [21]. One
important advantage of this method is the ability to rank
sites according to their strength (t-score). This gives an
approximate quantification of the residency time, and
allows us to stratify our analyses accordingly. The proce-
dure has highlighted an interesting difference in the local-
ization patterns between low and high stringency sites:
low stringency sites are enriched in close proximity to
TSSs, while strong sites show no bias in localization as
previously discussed [15,28]. Expectedly we find that the
number of predicted EREs increases with the stringency of
the observed sites, with 50% of highest stringency sites
showing a good match to a full ERE. This is less than the
71% reported in a Chip-pet study [18] which used a com-
parable definition of consensus match. This difference is
in line with the notion that ChIP-pet sites are enriched in
higher stringency sites as compared to the ChIP-chip sites
[15]. Finally we describe a nucleotide composition profile
showing a peak in GC bias within a narrow window (~200
bp) around the EREs; we note that this effect is uncoupled
SP1 acts as a cofactor for promoter proximal hERα sitesFigure 6
SP1 acts as a cofactor for promoter proximal hERα 
sites. Ranks of the induction scores are shown as boxplots in 
function of the number of promoter proximal (± 5 kbp 
around the TSS) ChIP sites with and without SP1 sites. The 
presence of SP1 motifs underlying promoter proximal ChIP 
sites increases the induction rank. Ranks are computed as in 
Fig. 5 and SP1 motifs are assigned to a ChIP site if the occu-
pancy is greater than 0.5 (Cf. Methods). Significance is 
assessed by Wilcoxon rank sum test.Page 8 of 13
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sites considered overlap with CpG islands (10% for t>10)
and the GC bias is unchanged if these are removed. Our
findings are in line with previous bioinformatics analyses
[29] which showed that regulatory regions have a biased
nucleotide composition compared to the rest of the
genome, in particular showing higher GC content than
expected. In addition, [13] stated that EREs with CG-rich
flanks are better predictors of functional regulatory bind-
ing sites. Considering that these authors performed an
unbiased search of the genome, their result matches our
observation that both low- and high-stringency ChIP-chip
sites are enriched in CG-content relative to the back-
ground (t<10).
Assigning hERα binding sites to target transcripts
Linking ChIP-chip sites to expression phenotypes requires
mapping of sites to transcripts. This is a notoriously diffi-
cult problem in higher eukaryotic organisms due to the
potential long-range regulation from distal enhancers. In
the absence of a better solution, the current practice is to
assign a site to a TSS according to proximity, using ad hoc
window sizes, both symmetrically and non-symmetrically
centered around TSSs. We assessed a variety of proposed
definitions in their ability to predict expression status of
target genes and found downstream sites to be equally
good or better predictors of hERα-mediated expression
than upstream sites. While it has been reported that ChIP
sites tend to be symmetrically distributed around TSSs for
Table 2: List of candidate targets of hERα. 
Gene symbol EREs FOX SP1 Association to ESR1
AFF3 1 1 0 Not yet reported
ANXA9 1 0 1 Not yet reported
ARL3 1 1 0 Not yet reported
ARSG 0 0 0 Estrogen signaling
ATRNL1 0 1 0 Not yet reported
C6orf97 1 1 0 Upstream of ESR1, no association reported
CELSR1 2 0 0 Cancer signature
CISH 1 0 0 Known target of ESR1
CXXC5 3 2 1 Not yet reported
CYP24A1 0 0 0 Breast cancer signature
DSCAM 2 3 0 Known target of ESR1
ERBB4 1 2 0 Estrogen signaling
FAM63A 1 0 1 Not yet reported
FSIP1 1 1 0 Not yet reported
GREB1 1 0 1 Known target of ESR1
IGF1R 1 2 0 Known target of ESR1
JMJD2B 2 1 1 Known target of ESR1
LMBR1 1 1 0 Anterior upper body development
MLPH 2 2 1 Anterior upper body development
MYB 1 1 0 Known target of ESR1
PARD6B 0 1 0 Known target of ESR1
PDZK1 2 3 0 Known target of ESR1
PKIB 2 2 0 Not yet reported
PREX1 2 1 0 Cancer signature
PTPRG 2 4 0 Known target of ESR1
RARA 1 0 0 Known target of ESR1
SFXN2 1 1 0 Not yet reported
SGK3 1 1 1 Cancer signature
SIAH2 2 2 0 Known target of ESR1
SLC22A5 1 1 0 Cancer signature
SLC9A3R1 3 1 0 Cancer signature
SPOCK1 1 1 0 Cancer signature
STARD10 1 1 0 Breast cancer signature
TFF1 1 1 1 Known target of ESR1
VAV3 2 3 0 Estrogen signaling
Each selected target shows at least two high stringency ChIP-chip sites and one ChIP-pet site along its transcript. In addition it scores in the 10% 
highest ranks in the combined rank list (cf. Fig. 5).
Column 1: Gene symbol. (UCSC genome browser, hg18).
Column 2–4: Number of binding motifs for hERα (EREs), FOX and SP1 respectively. EREs and FOX motifs are counted along the entire transcript, 
SP1 motifs are counted in ± 5 kbp of the TSS.
Column 5: Brief annotation of the known association of the target to estrogen activity, or to cancer. Breast cancer signature and cancer signature 
reflect upregulation of the corresponding transcript in one of the reported conditions.Page 9 of 13
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increased performance of downstream sites is due to fewer
ambiguous assignments to transcripts when genes are
closely spaced.
Functional signatures of cofactor elements near hERα sites
Several transcription regulators and chromatin remode-
ling factors have been shown to interact with hERα.
Recently, [15] demonstrated that hERα and FOXA1 inter-
act over long ranges while [17] argued that hERα and
FOXA1 may reciprocally help each other in stabilizing
binding to DNA. Moreover ERE independent gene activa-
tion relying on hERα/SP1 complexes at GC-rich sites has
been reported [31]. We therefore used our metrics to study
the influence of FOX and SP1 cofactor sites near hERα
ChIP sites on the induction of target genes. Consistent
with the aforementioned hERα/SP1 mode of regulation
we find that promoter proximal sites are much more effec-
tive at inducing expression when they co-occur with an
SP1 site.
Two models for hERα target regulation
Taken together, these data suggest two hypotheses: (i)
weak DNA interactions, in particular at promoters, repre-
sent degenerate EREs bound by hERα and compensated
by the presence of cofactors; (ii) alternatively, these weak
ChIP signals are the result of cross-linking of long-range
interaction of hERα with its promoter-bound partners.
Both scenarios are consistent with our analysis. In support
of the first we showed that promoter proximal ChIP bind-
ing sites, i.e. in centered windows of 5 kbp, are associated
with gene induction (Fig. 4). Moreover, genes with SP1
motifs in their promoter sequences show strong estro-
genic response independently of EREs (Fig. 6). However,
our finding that consideration of downstream sites far
from promoters increases the selection of induced genes
would favor the second model in which hERα-mediated
induction of target genes is more prominently regulated
through long-range interactions. Indeed, we find that the
number of ChIP sites along the transcript is the best dis-
criminator for highly responsive genes (Fig. 5 and [see
Additional file 7]). In this analysis, the occurrence of
cofactor motifs, i.e. FOX, only marginally improves the
discrimination of highly induced target genes (Fig. 5).
Data integration and high confidence hERα targets
An admitted caveat of independent location and expres-
sion studies is that the list of predicted targets can be quite
large [20]. Crossing results from several studies will likely
form a core group of the most robust targets. In this con-
text, we applied stringent criteria to define a list of high
confidence direct targets. We found that there was a dis-
tinction between targets associated to normal conditions
and targets which are most prominent in pathological
states. Namely, known targets and targets related to estro-
gen signaling and fore-body development are rich in both
EREs and FOX motifs, but they also show the presence of
SP1 sites (Table 2). On the other hand, targets that have
been reported in cancer studies, probably reflecting
abnormal hERα activity at binding sites, exhibit many
EREs but no SP1 motifs at promoters and few FOX sites
along the transcripts (Table 2).
Conclusion
We investigated the influence of hERα binding patterns,
as detected by ChIP, on expression phenotypes in cell cul-
ture and cancer tissues, measured by microarray. Further-
more, the availability of a ChIP-chip dataset [15] and a
ChIP-pet dataset [18] enabled the direct comparison of
the two technologies. ChIP-chip being sensitive to cross-
linking, the methodology can be informative in detecting
weaker or transient enrichment at promoters. The present
study highlights how such weak sites show different func-
tional signatures from the stronger sites. ChIP-pet, on the
other hand, selects stronger sites and offers higher posi-
tional resolution. Localizing binding elements in silico
using genomic sequence analysis in conjunction with
ChIP helps stratify sites and highlight relevant features
underlying induction by hER.
Taken together, our analyses support the model that hERα
mediated response to estrogen signaling occurs over long-
range interactions with SP1 or other promoter-proximal
cofactors. The strength of the response is in quantitative
linkage with the number of hERα binding sites along tar-
get transcripts. We found that the intragenic fraction of
bound hERα is the best discriminator of estrogen respon-
sive genes. In particular, our main finding is that the
number of hERα binding sites along the transcripts of tar-
get genes is correlated with the strength of the response.
This highlights the quantitative nature of the hERα-medi-
ated response to estrogen.
Methods
Genomic data
Genomic sequence, annotations and chromosomal coor-
dinates of transcription start sites (TSSs) are publicly avail-
able from the UCSC Genome Table browser [32]. Based
on these coordinates, we define "genes" as the genomic
regions from 5 kb upstream of the TSS to 5 kb down-
stream of the polyadenylation site (PAS), accounting for
roughly 30% of the chromosomes length. We use the
genome build hg18.
ChIP data
Shirley Liu provided the raw ChIP-chip data upon request
[15].
In brief, estrogen receptor proteins were cross-linked to
DNA and purified using specific antibodies. Fragments
were amplified with random primers and hybridized on
Affymetrix Human tiling arrays, covering the non-repeti-Page 10 of 13
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provides three technical replicas [15]. To quantify the
enrichment we used our SLM algorithm [21] without
applying the resampling technique to control the false dis-
covery proportion.
The coordinates of the ChIP-pet study are publicly availa-
ble online [18].
Expression microarray data and induction scores
The compendium of cancer expression was used to derive
the partial correlations of every gene in the genome, as in
the following
Where  is the expression level of gene g in condition i;
α, β, γ, δ and λ are the partial correlations. The genes ESR1,
ERB2, AURRA, PLAU and STAT1 correspond to estrogen
pathway, 17q amplification, proliferation, stroma and
immune respone, respectively.
The method is a linear model, fitted separatedly for each
dataset in [12]. Each term produces a partial (adjusted)
correlation. The partial correlations are combined across
datasets using the Fisher's hyperbolic tangent formula.
The partial correlation to ESR1, α, has been used in the
present study.
The primary hERα target study is publicly available [20];
it consists of triplicates of 4 conditions: 2 conditions cor-
respond to the estrogen induction (ER+) with and without
cycloheximide (CHX+ and CHX-), and 2 conditions corre-
spond to a mock induction non-estrogen related (ER-),
with and without cycloheximide. We build two regression
models to describe gene expression levels:
where i is the condition index, Ig is a gene-dependent
intercept, ag, bg, a'g and b'g are the regression coefficients, δ
i is an indicator function taking value 1 when the condi-
tion expressed in i is satisfied, 0 otherwise. We reason that
the M1 model is suited for direct targets, therefore, since
cycloheximide inhibits expression of secondary targets,
the inequality ag <a'g will be true for indirect targets. The
induction score is the rank of the difference between ag
and a'g.
We also consider other two publicly available MCF7 stud-
ies [15,33].
The estrogen dosage study [33] consists of 5 replicates of
5 conditions corresponding to the following concentra-
tions of estrogen: 0 pM, 10 pM, 30 pM, 60 pM and 100
pM. We model the expression level of gene g according to
the following linear regression model:
where Ig is a gene-dependent intercept, ag and bg are the
regression coefficients, M is a metagene averaging the
expression levels of known responsive target genes of
hERα (tff1, rara, slc25a36, ddef2, wfikkn2, bcr) [19] and P
is a metagene averaging the expression levels of prolifera-
tion related genes (vcy, pry, fam127a, ine1, serf1a, qser1,
hbg1, opn1mw, akap2) [34]. ag is the induction score.
The estrogen exposure study [15] consists of triplicates of
4 time points at which the population of MCF7 cells has
been sampled and hybridized on the microarray: 0 h, 3 h,
6 h and 12 h. We model the expression levels of each gene
similarly as in the estrogen dosage study. ag is the induc-
tion score.
Multilinear regression parameters and statistics are com-
puted using the software R http://cran.r-project.org.
Transcription factor position weight matrices (PWMs)
Position weight matrices (PWMs) were used to define
consensus sites for transcription factors. To compute
occupancies, PWMs were then embedded in Hidden
Markov Models. The TRANSFAC [35] hERα PWM matrix,
19 bases wide, is poorly polarized for the first half of the
dimer ([see Additional file 8], panel A), thus correspond-
ing to an information content of 10.3 bits. By compari-
son, the TRANSFAC human E-box matrix, only 10 bases
wide, carries 8.8 bits of information. In order to improve
the ERE signal within the hERα PWM we recovered a de
novo hERα PWM from the ChIP-chip data. Specifically we
collected the ChIP-chip sites with t>16, and we analyzed
the 250 underlying sequences that best matched the
TRANSFAC matrix with MEME [36]. MEME identified a
hERα motif as the strongest signal in our collection of
sequences. We generated our de novo hERα PWM from
the nucleotide composition of the sites recovered by
MEME. A pseudocount of 1 nucleotide per position is
included. Our hERα PWM matrix has an information con-
tent of 16 bits ([see Additional file 8], panel B, logo and
frequency matrix).
The other PWM matrices used in the study are available on
TRANSFAC [35]. When multiple matrices are available,
we consider the one with the largest information content.
The used matrices are: HNF3ALPHA_Q6_V_M00724 for
FOXA1, E2F1_Q4_01_V_M00939 for E2F, AP1_Q6_
01_V_M00925 for AP1 and SP1_Q6_01_M00196 for SP1.
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To infer a probabilistic segmentation of a sequence in
terms of background and non-overlapping binding sites
for a given set of transcription factors, we design a stand-
ard Hidden Markov Model (HMM). The emission fre-
quencies for binding sites are taken from the
aforementioned PWMs. The emission frequencies for the
background state (0-order) are taken as the total genomic
frequencies in human. We use a custom posterior decod-
ing algorithm [37] to calculate the occupancy n at each
site for each of the factors PWM. The graph of the multiple
PWMs Markov chain of the hidden states implemented in
the study is depicted in [see Additional file 1].
ROC analysis
In the ROC analysis we compare discriminators (e.g. the
number of sites along the transcript) to response variables
(e.g. induction score measured on expression microar-
rays). We consider the 1% of most induced genes as gen-
uine estrogen responsive genes. For each discriminator,
we apply a sliding cutoff x to define a set of predicted pos-
itives P with X>x. The set of true positives, TP, corresponds
to the elements in P which are also genuine estrogen
responsive genes. Similarly, the set of false positives, FP,
corresponds to the fraction of P which are not in the 1%
of most induced genes. The set of negatives, N is the com-
plementary to P. The false negatives, FN, are defined as the
elements of N which are in the top 1% of most induced
genes. The true negatives, TN, can be easily derived as TN
= N-FN. We define sensitivity as the ratio TP/(TP+FN).
Specificity is defined as TN/(FP+TN).
Abbreviations
hERα: human estrogen receptor α; SP1: specificity factor
1; ERE: estrogen responsive elements; TSS: transcription
start site; ChIP: chromatin-immunoprecipitation; ChIP-
pet: ChIP paired end diTags; HMM: Hidden Markov
Model; PAS: poly-adenylation site; ROC: receiver operat-
ing characteristic; PWMs: Position weight matrices; P: pos-
itives; N: negatives; TP: true positives; TN: true negatives;
FP: false positives; FN: false negatives.
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Supplemental Figure S3. ROC analysis for comparing the ability of 
upstream or downstream ChIP sites to predict induced genes.




Supplemental Figure S4. ROC analysis to compare the ability of ChIP 
sites in variably sized windows to predict induced genes: cancer expression 
compendium and primary targets.
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sites in variably sized windows to predict induced genes: estrogen exposure 
and dosage datasets.




Supplemental Figure S6. Comparison of log-likelihood distributions of 
the FOX factors PWMs for the ChIP sites with t>16.




Supplemental Figure S7. Response to hERα increases in function of the 
number of ChIP sites along transcripts: only primary target dataset.
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ces (PWMs).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-381-S8.pdf]Page 12 of 13
(page number not for citation purposes)
BMC Genomics 2009, 10:381 http://www.biomedcentral.com/1471-2164/10/381Acknowledgements
FP, BS, MD and FN are grateful to the NCCR Molecular Oncology program 
for financial support. We thank Shirley Liu for providing the raw ChIP chip 
data and Bart Deplancke for interesting comments on the manuscript.
References
1. Jordan VC: The past, present, and future of selective estrogen
receptor modulation.  Ann N Y Acad Sci 2001, 949:72-79.
2. Ali S, Coombes RC: Endocrine-responsive breast cancer and
strategies for combating resistance.  Nat Rev Cancer 2002,
2(2):101-112.
3. Simpson ER: Sources of estrogen and their importance.  J Ster-
oid Biochem Mol Biol 2003, 86(3–5):225-230.
4. Walker P, Germond JE, Brown-Luedi M, Givel F, Wahli W:
Sequence homologies in the region preceding the transcrip-
tion initiation site of the liver estrogen-responsive vitello-
genin and apo-VLDLII genes.  Nucleic Acids Res 1984,
12(22):8611-8626.
5. Sanchez R, Nguyen D, Rocha W, White JH, Mader S: Diversity in
the mechanisms of gene regulation by estrogen receptors.
Bioessays 2002, 24(3):244-254.
6. Klinge CM: Estrogen receptor interaction with estrogen
response elements.  Nucleic Acids Res 2001, 29(14):2905-2919.
7. Kininis M, Kraus WL: A global view of transcriptional regula-
tion by nuclear receptors: gene expression, factor localiza-
tion, and DNA sequence analysis.  Nucl Recept Signal 2008,
6:e005.
8. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM,
Webb P: Estrogen receptor pathways to AP-1.  J Steroid Biochem
Mol Biol 2000, 74(5):311-317.
9. Safe S, Abdelrahim M: Sp transcription factor family and its role
in cancer.  Eur J Cancer 2005, 41(16):2438-2448.
10. McKenna NJ, Lanz RB, O'Malley BW: Nuclear receptor coregula-
tors: cellular and molecular biology.  Endocr Rev 1999,
20(3):321-344.
11. Hermanson O, Glass CK, Rosenfeld MG: Nuclear receptor coreg-
ulators: multiple modes of modification.  Trends Endocrinol
Metab 2002, 13(2):55-60.
12. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains
B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, et al.: Meta-analy-
sis of gene expression profiles in breast cancer: toward a uni-
fied understanding of breast cancer subtyping and prognosis
signatures.  Breast Cancer Res 2008, 10(4):R65.
13. Vega VB, Lin CY, Lai KS, Kong SL, Xie M, Su X, Teh HF, Thomsen JS,
Yeo AL, Sung WK, et al.: Multiplatform genome-wide identifica-
tion and modeling of functional human estrogen receptor
binding sites.  Genome Biol 2006, 7(9):R82.
14. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute
J, Shao W, Hestermann EV, Geistlinger TR, et al.: Chromosome-
wide mapping of estrogen receptor binding reveals long-
range regulation requiring the forkhead protein FoxA1.  Cell
2005, 122(1):33-43.
15. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brod-
sky AS, Keeton EK, Fertuck KC, Hall GF, et al.: Genome-wide anal-
ysis of estrogen receptor binding sites.  Nat Genet 2006,
38(11):1289-1297.
16. Kwon YS, Garcia-Bassets I, Hutt KR, Cheng CS, Jin M, Liu D, Benner
C, Wang D, Ye Z, Bibikova M, et al.: Sensitive ChIP-DSL technol-
ogy reveals an extensive estrogen receptor alpha-binding
program on human gene promoters.  Proc Natl Acad Sci USA
2007, 104(12):4852-4857.
17. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll
JS, Liu XS, Brown M: FoxA1 translates epigenetic signatures
into enhancer-driven lineage-specific transcription.  Cell 2008,
132(6):958-970.
18. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP,
Lipovich L, Barnett DH, Stossi F, et al.: Whole-genome cartogra-
phy of estrogen receptor alpha binding sites.  PLoS Genet 2007,
3(6):e87.
19. Laganiere J, Deblois G, Giguere V: Functional genomics identifies
a mechanism for estrogen activation of the retinoic acid
receptor alpha1 gene in breast cancer cells.  Mol Endocrinol
2005, 19(6):1584-1592.
20. Bourdeau V, Deschenes J, Laperriere D, Aid M, White JH, Mader S:
Mechanisms of primary and secondary estrogen target gene
regulation in breast cancer cells.  Nucleic Acids Res 2008,
36(1):76-93.
21. Parisi F, Wirapati P, Naef F: Identifying synergistic regulation
involving c-Myc and sp1 in human tissues.  Nucleic Acids Res
2007, 35(4):1098-1107.
22. Courey AJ, Holtzman DA, Jackson SP, Tjian R: Synergistic activa-
tion by the glutamine-rich domains of human transcription
factor Sp1.  Cell 1989, 59(5):827-836.
23. Kadonaga JT, Courey AJ, Ladika J, Tjian R: Distinct regions of Sp1
modulate DNA binding and transcriptional activation.  Sci-
ence 1988, 242(4885):1566-1570.
24. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D,
Piccolboni A, Sementchenko V, Cheng J, Williams AJ, et al.: Unbiased
mapping of transcription factor binding sites along human
chromosomes 21 and 22 points to widespread regulation of
noncoding RNAs.  Cell 2004, 116(4):499-509.
25. Olayioye MA, Hoffmann P, Pomorski T, Armes J, Simpson RJ, Kemp
BE, Lindeman GJ, Visvader JE: The phosphoprotein StarD10 is
overexpressed in breast cancer and cooperates with ErbB
receptors in cellular transformation.  Cancer Res 2004,
64(10):3538-3544.
26. Olayioye MA, Vehring S, Muller P, Herrmann A, Schiller J, Thiele C,
Lindeman GJ, Visvader JE, Pomorski T: StarD10, a START domain
protein overexpressed in breast cancer, functions as a phos-
pholipid transfer protein.  J Biol Chem 2005,
280(29):27436-27442.
27. Davis LM, Harris C, Tang L, Doherty P, Hraber P, Sakai Y, Bocklage
T, Doeden K, Hall B, Alsobrook J, et al.: Amplification patterns of
three genomic regions predict distant recurrence in breast
carcinoma.  J Mol Diagn 2007, 9(3):327-336.
28. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Hue-
bert DJ, McMahon S, Karlsson EK, Kulbokas EJ 3rd, Gingeras TR, et
al.: Genomic maps and comparative analysis of histone mod-
ifications in human and mouse.  Cell 2005, 120(2):169-181.
29. Blanchette M, Bataille AR, Chen X, Poitras C, Laganiere J, Lefebvre C,
Deblois G, Giguere V, Ferretti V, Bergeron D, et al.: Genome-wide
computational prediction of transcriptional regulatory mod-
ules reveals new insights into human gene expression.
Genome Res 2006, 16(5):656-668.
30. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR,
Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE, et al.:
Identification and analysis of functional elements in 1% of the
human genome by the ENCODE pilot project.  Nature 2007,
447(7146):799-816.
31. Khan S, Abdelrahim M, Samudio I, Safe S: Estrogen receptor/Sp1
complexes are required for induction of cad gene expression
by 17beta-estradiol in breast cancer cells.  Endocrinology 2003,
144(6):2325-2335.
32. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler
D, Kent WJ: The UCSC Table Browser data retrieval tool.
Nucleic Acids Res 2004:D493-496.
33. Coser KR, Chesnes J, Hur J, Ray S, Isselbacher KJ, Shioda T: Global
analysis of ligand sensitivity of estrogen inducible and sup-
pressible genes in MCF7/BUS breast cancer cells by DNA
microarray.  Proc Natl Acad Sci USA 2003, 100(24):13994-13999.
34. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H,
Farmer P, Praz V, Haibe-Kains B, et al.: Gene expression profiling
in breast cancer: understanding the molecular basis of histo-
logic grade to improve prognosis.  J Natl Cancer Inst 2006,
98(4):262-272.
35. Wingender E, Dietze P, Karas H, Knuppel R: TRANSFAC: a data-
base on transcription factors and their DNA binding sites.
Nucleic Acids Res 1996, 24(1):238-241.
36. Bailey TL, Williams N, Misleh C, Li WW: MEME: discovering and
analyzing DNA and protein sequence motifs.  Nucleic Acids Res
2006:W369-373.
37. Durbin R, Eddy S, Krogh A, Mitchison G: Biological sequence anal-
ysis.  Cambridge University Press, Cambridge; 1998. Page 13 of 13
(page number not for citation purposes)
